skincaremanual.org

Scientists discover new candidate gene for Dravet syndrome

April 30, 2017

P.K. Burnette, Pharm.D., Ph.D., will discuss human telomerase reverse transcription deficiency in MDS. Michal Jaglal, M.D., and Rami S. Komrokji, M.D., will present data on the efficacy of chemotherapy drugs for secondary acute myeloid leukemia following Azanucleosides failure. Komrokji will report on a study examining the inhibitor ARRY-614 in patients with MDS and also on a phase II study on a novel inhibitor for treating thrombocythemia myelofibrosis. Mikkael Sekeres, M.D., and Komrokji will review the final results from a phase II continuation study on lenalidomide and azacitidine in combination for patients with higher risk MDS. Sheng Wei, M.D., Ph.D., will report on a study examining the role of myeloid-derived suppressor cells in the pathogenesis of MDS.

Lymphoma and myeloma researchers

Beata Holkova, M.D., and Lubomir Sokol, M.D., Ph.D., will discuss a phase II clinical trial for mantle cell lymphoma and diffuse large B-cell lymphoma. Fengdong Cheng, M.D., and Eduardo Sotomayor, M.D., will present on the role of Histone deacetylase 6 and STAT3 in IL-10 gene expression and immune tolerance mediated by antigen-presenting cells. Hong Wei Wang, M.D., and Sotomayor will share data on Tubastatin A, a selective HDAC6 inhibitor that enhances antigen-presenting cell function and restores the responsiveness of tolerant CD4+ T cells. Bertrand Coiffier, M.D., and Sokol will present an analysis of a phase II study of romidepsin for patients with relapsed or refractory common peripheral T-cell lymphoma subtypes. Burnette will discuss mediation by pro-fibrotic mesenchymal stem cells in the bone marrow niche for cytopenias in large cell granular lymphocytic leukemia. Karrune Woan, B.S., and Sotomayor will report on the role of histone deacetylase 11 (HDAC11) as a regulatory checkpoint of T-cell function. Benjamin Djulbegovic, M.D., Ph.D., will discuss the impact of the National Cancer Institute's "Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment-Related Harms Reporting."

Source: H. Lee Moffitt Cancer Center & Research Institute